1
|
Ducreux M, Abou-Alfa GK, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet JM, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O'Connor JM, O'Reilly EM, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022. ESMO Open 2023; 8:101567. [PMID: 37263081 PMCID: PMC10245111 DOI: 10.1016/j.esmoop.2023.101567] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 04/20/2023] [Accepted: 04/24/2023] [Indexed: 06/03/2023] Open
Abstract
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.
Collapse
Affiliation(s)
- M Ducreux
- Université Paris-Saclay, Gustave Roussy, Villejuif, France.
| | - G K Abou-Alfa
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA; Trinity College Dublin, Dublin, Ireland
| | | | - J Berlin
- Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - A Cervantes
- INCLIVA, Biomedical Research Institute, Hospital Clínico Universitario, University of Valencia, Valencia, Spain
| | - T de Baere
- Université Paris-Saclay, Gustave Roussy, Villejuif, France
| | - C Eng
- Vanderbilt-Ingram Cancer Center, Nashville, USA
| | - P Galle
- University Medical Center Mainz, Mainz, Germany
| | - S Gill
- BC Cancer/University of British Columbia, Vancouver, Canada
| | - T Gruenberger
- Clinic Favoriten, HPB Center Health Network Vienna and Sigmund Freud University, Medical School, Vienna, Austria
| | - K Haustermans
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| | - A Lamarca
- Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - P Laurent-Puig
- Institut du cancer Paris CARPEM, APHP, Georges Pompidou Hospital, Université Paris Cité, Paris, France
| | - J M Llovet
- Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Universitat de Barcelona, Barcelona; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
| | - F Lordick
- University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany
| | - T Macarulla
- Vall d'Hebron Hospital Campus, Barcelona, Spain; Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
| | - D Mukherji
- American University of Beirut, Beirut, Lebanon
| | - K Muro
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - R Obermannova
- Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic
| | - J-M O'Connor
- Instituto Alexander Fleming, Buenos Aires, Argentina
| | - E M O'Reilly
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA
| | - P Osterlund
- Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Tampere University Hospital, University of Tampere, Tampere, Finland
| | - P Philip
- Henry Ford Cancer Institute, Departments of Oncology and Pharmacology, Wayne State University, Detroit, USA
| | - G Prager
- Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
| | | | - B Sangro
- Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
| | | | - J Tabernero
- Vall d'Hebron Hospital Campus and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain
| | - C Verslype
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| | - H Wasan
- Hammersmith Hospital, Imperial College London, London, UK
| | - E Van Cutsem
- University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium
| |
Collapse
|
2
|
Calderillo-Ruiz G, Herrera M, Takahashi A, Diaz C, Ruiz-Garcia E, Lopez Basave H, Carbajal-López B, Albarran A, García-Gámez M. P-130 Latin American population with adenocarcinoma of the esophagogastric junction: A 9-year follow up. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
3
|
Ruiz-Garcia E, Calderillo-Ruiz G, Peña-Nieves A, Diaz C, Herrera M, Takahashi A, Fernandez-Figueroa E. P-304 Prognostic impact of clinicopathological characteristics on gastrointestinal stromal tumors in a Latin population. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Ruiz-Garcia E, Garcilazo A, Calderillo-Ruiz G, Diaz C, Herrera M, Peña-Nieves A, Melchor-Ruan J. P-254 The prevalence of pancreatic cancer-associated thrombosis in Mexican patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Calderillo-Ruiz G, Diaz C, Villanueva Domínguez J, Lopez Basave H, Carbajal-López B, Ruiz-Garcia E, Herrera M, Muñoz W, Itzel V, Perez Plascencia C. P-128 Pathologic complete response to neoadjuvant chemoradiation as a predictor of survival in Latin American patients with rectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Cesca M, Ruiz-Garcia E, Weschenfelder R, D'Agustini N, Iseas S, Pereira A, Mello C, Riechelmann R. P-197 The influence of proton pump inhibitor utilization on the pathological response of rectal cancer: A multicenter study by the Sociedad Latino Americana de Oncologia Gastrointestinal (SLAGO). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
7
|
Calderillo-Ruiz G, Diaz C, Heredia D, Carbajal-López B, Basave HL, Itzel V, Ruiz-Garcia E, Herrera A, Meneses-Garcia A. P-226 Analysis of Hispanic Latino American patients with colorectal cancer, clinical features and laterality as a prognosis factor of overall survival. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
8
|
Calderillo-Ruiz G, Lopez H, Diaz C, Ruiz-Garcia E, Carbajal B, Gomez A. Impact of ileostomy in the adjuvant treatment of colorectal cancer stages II-III. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Diaz C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, Manuel F, Horacio L, Ruiz-Garcia E, Itzel V, Ruan J, Miranda G, Gomez A, Meneses A. Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Ramos-Ramirez M, Diaz C, Calderillo-Ruiz G, Navia L, Herrera M, Espinosa-Ramirez J, Ruiz-Garcia E. Nutritional index differential as a prognostic factor for recurrence in patients with locally advanced rectal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Diaz C, Calderillo-Ruiz G, Herrera M, Ramos-Ramirez M, Ruiz-Garcia E, Takahashi A, Calderillo V, Horacio L. Prospective clinical study phase IIa open-label and not randomized of efficacy and toxicity of weekly paclitaxel chemotherapy in patients with advanced esophagogastric adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Arce-Salinas C, Deneken-Hernandez Z, Flores-Diaz D, Gonzalez-Serrano JP, Matus-Santos JA, Ruiz-Garcia E, Calderillo-Ruiz G, Macedo O, Santamaría-Galicia J, Aguilar-Ponce JL, Reynoso-Noverón N. Abstract P1-11-14: Efficacy and quality of life analysis of palonosetron vs ondansetron for high and moderate emetogenic chemotherapy for breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-14] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Nausea and vomiting are common complications on the chemotherapy (CINV) and can affect the quality of life of the patients. There are various antiemetic regiments that varies in both cost and effectiveness. The aim of this trial is to evaluate the efficacy in acute and delayed CINV of ondansetron vs palonosetron.
Patients and methods: In his was a randomized, open label trial, we included breast cancer patients' candidate to (AC, TC, TCH regimens); arm A received palonosetron, dexamethasone and fosaprepitant and arm B ondansetron, dexamethasone, fosaprepitant; patients who had received previously any chemotherapy or radiotherapy were excluded.Presence of CINV were investigated, as well the ER visits due for CINV and QoL (EORTC QLQ 30 and EORTC B-23) were analyzed during the first cycle of treatment. Local ethics committee approved the trial.
Results: 262 patients were included, 87% received AC and 13% TC; acute control was achieved in 87% and 94% respectively, p=ns and delayed control was achieved in 76% and 86% p=ns, toxicity was similar in both arms. QoL analysis showed no differences in family interaction, social life and financial troubles. ER visits due to severe symptoms were similar p=ns
Conclusions: Palonosetron or ondansetron are equally effective in prevention acute and delayed CINV and they also maintain similar quality of life.
Citation Format: Arce-Salinas C, Deneken-Hernandez Z, Flores-Diaz D, Gonzalez-Serrano JP, Matus-Santos JA, Ruiz-Garcia E, Calderillo-Ruiz G, Macedo O, Santamaría-Galicia J, Aguilar-Ponce JL, Reynoso-Noverón N. Efficacy and quality of life analysis of palonosetron vs ondansetron for high and moderate emetogenic chemotherapy for breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-14.
Collapse
Affiliation(s)
- C Arce-Salinas
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - Z Deneken-Hernandez
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - D Flores-Diaz
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - JP Gonzalez-Serrano
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - JA Matus-Santos
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - E Ruiz-Garcia
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - G Calderillo-Ruiz
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - O Macedo
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - J Santamaría-Galicia
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - JL Aguilar-Ponce
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| | - N Reynoso-Noverón
- Instituto Nacional de Cancerologia, Mexico, CDMX, Mexico; FUCAM-IEM, Mexico, CDMX, Mexico
| |
Collapse
|
13
|
Astudillo-de la Vega H, Alonso-Luna O, Ali-Pérez J, López-Camarillo C, Ruiz-Garcia E. Oncobiome at the Forefront of a Novel Molecular Mechanism to Understand the Microbiome and Cancer. Adv Exp Med Biol 2019; 1168:147-156. [PMID: 31713170 DOI: 10.1007/978-3-030-24100-1_10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The microbiome comprises all the genetic material within a microbiota, that represents tenfold higher than that of our cells. The microbiota it includes a wide variety of microorganisms such as bacteria, viruses, protozoans, fungi, and archaea, and this ecosystem is personalized in any body space of every individual. Balanced microbial communities can positively contribute to training the immune system and maintaining immune homeostasis. Dysbiosis is a change in the normal microbiome composition that can initiate chronic inflammation, epithelial barrier breaches, and overgrowth of harmful bacteria. The next-generation sequencing methods have revolutionized the study of the microbiome. Bioinformatic tools to manage large volumes of new information, it became possible to assess species diversity and measure dynamic fluctuations in microbial communities. The burden of infections that are associated to human cancer is increasing but is underappreciated by the cancer research community. The rich content in microbes of normal and tumoral tissue reflect could be defining diverse physiological or pathological states. Genomic research has emerged a new focus on the interplay between the human microbiome and carcinogenesis and has been termed the 'oncobiome'. The interactions among the microbiota in all epithelium, induce changes in the host immune interactions and can be a cause of cancer. Microbes have been shown to have systemic effects on the host that influence the efficacy of anticancer drugs. Metagenomics allows to investigate the composition of microbial community. Metatranscriptome analysis applies RNA sequencing to microbial samples to determine which species are present. Cancer can be caused by changes in the microbiome. The roles of individual microbial species in cancer progression have been identified long ago for various tissue types. The identification of microbiomes of drug resistance in the treatment of cancer patients has been the subject of numerous microbiome studies. The complexity of cancer genetic alterations becomes irrelevant in certain cancers to explain the origin, the cause or the oncogenic maintenance by the oncogene addiction theory.
Collapse
Affiliation(s)
- H Astudillo-de la Vega
- Translational Research Laboratory in Cancer & Celullar Therapy, Hospital de Oncologia, Siglo XXI, IMSS, Mexico City, Mexico.
| | - O Alonso-Luna
- Laboratorio de NGS, Nanopharmacia Diagnostica de la Ciudad de Mexico, Mexico City, Mexico
| | - J Ali-Pérez
- Laboratorio de Oncogenomica, Nanopharmacia Diagnostica de la Ciudad de Mexico, Mexico City, Mexico
| | - C López-Camarillo
- Posgrado en Ciencias Genomicas, Universidad Autonoma de la Ciudad de Mexico, Mexico City, Mexico
| | - E Ruiz-Garcia
- Department of Gastrointestinal Medical Oncology & Translational Medicine Laboratory, Instituto Nacional de Cancerologia, Mexico City, Mexico
| |
Collapse
|
14
|
Moreno JZ, Aiello-Crocifoglio V, Pantoja BG, Ruiz-Garcia E, Estrada G, Baillet F. Long term survival in advanced esophageal cancer, treated with a French modality of hypofractionated radiotherapy + chemotherapy with or without surgery, the experience at the Instituto Nacional de Cancerología, México. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Zamora Moreno J, Ruiz-Garcia E, Mitsoura E, Estrada G, Aiello Crocifoglio V. P-218 Survival in incidental gallbladder cancer treated with short-course radiotherapy after simple cholecystectomy without re-exploration, and evaluation of tumor biomarkers: The experience at The National Cancer Institute (México). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.210] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Calderillo G, Herrera M, Lopez H, Diaz C, Padilla A, Ruiz-Garcia E, Trejo E. P-130 Impact of age on efficacy of neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Diaz C, Calderillo G, Marytere H, Ruiz-Garcia E, Manuel F, Trejo E, Horacio L, J Luis A, Herrera A, Meneses A, Alejandro P. P-132 The impact of obesity on complete pathologic response to neoadjuvant chemoradiotherapy in rectal cancer patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw199.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Vega HADL, Romero-Garcia P, Silva J, Villalobos-Valencia R, Vazquez-Rivera V, Ruiz-Calzada H, Lopez-Yañez A, Cortes-Esteban P, Calderillo-Ruiz G, Ruiz-Garcia E. 1101 POSTER Identification of KRas Mutational Polymorphism by Molecular Analysis Using High-resolution Melting System in a Large MCRC Mexican Sample. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70744-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
19
|
Ruiz-Garcia E, Scott V, Machavoine C, Bidart JM, Lacroix L, Delaloge S, Andre F. Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening. Br J Cancer 2010; 102:462-8. [PMID: 20068563 PMCID: PMC2822945 DOI: 10.1038/sj.bjc.6605511] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2009] [Revised: 11/21/2009] [Accepted: 11/29/2009] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate biomarkers for blood-based screening. METHODS We identified two proteins (Fibronectin 1 and CXCL9) from a gene expression data set that included 120 BC samples and 45 benign lesions. These proteins fulfil the following criteria: differential gene expression between cancer and benign lesion, protein released in the extracellular medium and stable in the serum, commercially available ELISA kit, ELISA accuracy in a feasibility study. Protein concentrations were determined by ELISA. Blood samples were from normal volunteers (n=119) and early BC patients (n=133). RESULTS Seventy-three per cent of patients had cT1-T2 tumour. Patients had higher CXCL9 and Fibronectin 1 concentrations than volunteers. CXCL9 mean concentration was 851 and 635 pg ml(-1) for patients and volunteers respectively (P=0.013). CXCL9 concentration was significantly higher in patients with estrogen receptor (ER)-negative compared with volunteers (P=0.003), data consistent with gene expression profile. Fibronectin 1 mean concentration was 190 microg ml(-1) for patients and 125 microg ml(-1) for volunteers (P<0.001). Areas under the curve for BC diagnosis were 0.78 and 0.62 for Fibronectin 1 and CXCL9 respectively. A combined score including Fibronectin 1 and CXCL9 dosages presented 53% of sensitivity and 98% of specificity. Similar performances were observed for ER-negative tumours. CONCLUSIONS This study suggests that Fibronectin 1/CXCL9 dosage in serum could screen a significant rate of BC, including ER-negative, and that differential gene expression analysis is a good approach to select candidate biomarkers to set up blood assays cancer screening.
Collapse
Affiliation(s)
- E Ruiz-Garcia
- Breast Cancer Translational Research Unit, UPRES EA03535, Université Paris XI, Institut Gustave Roussy, Villejuif, France
| | - V Scott
- Breast Cancer Translational Research Unit, UPRES EA03535, Université Paris XI, Institut Gustave Roussy, Villejuif, France
| | - C Machavoine
- Department of Laboratory Medicine, Institut Gustave Roussy, Villejuif, France
| | - J M Bidart
- Department of Laboratory Medicine, Institut Gustave Roussy, Villejuif, France
| | - L Lacroix
- Department of Laboratory Medicine, Institut Gustave Roussy, Villejuif, France
| | - S Delaloge
- Breast Cancer Translational Research Unit, UPRES EA03535, Université Paris XI, Institut Gustave Roussy, Villejuif, France
- Breast Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
| | - F Andre
- Breast Cancer Translational Research Unit, UPRES EA03535, Université Paris XI, Institut Gustave Roussy, Villejuif, France
- Breast Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
20
|
Garcia-Hernandez N, Arenas D, Murillo-Ortiz B, Meneses A, Muñoz D, Ruiz-Garcia E, Astudillo-de la Vega H. Biomarker analysis by tissue microarray technology of Bik, Bcl-2, Bax, ER-α, ER-β, Her2/neu, PCNA, P53, pRB proteins and apoptotic index (by TUNEL) in breast cancer Mexican biopsies. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-4043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #4043
Background: 
 The development and progression of epithelial cancers are the results of changes in many genetic networks. Through massive analysis techniques various prognostic factors have been studied to determine proteins implicated in cancer. A new technology used is tissue microarray (TMAs), which allows the assessment of several patients at different stages in a single slide.
 Methods:
 TMA blocks with up to 128 cylinders were made by using 1.5-mm diameter tissue cores from each paraffin block. In a series of 70 formalin-fixed carcinomas, we analyzed the immuno-expression of Bik, Bcl-2, Bax, ER-α, ER-β, Her2, PCNA, P53 and RB proteins. For apoptosis detection the TUNEL technique was used. Expression profiles for these tumors were generated with an unsupervised clustering and a T Test analysis.
 Results:
 We developed TMAs with samples from Mexican women with breast cancer at different stages (type I, II and III) and compared these with those of non affected breast tissue of the same women's samples. Through a hierarchical cluster we found three subgroups of tumors according to protein expression behavior. The apoptotic process was found in low grade 4.28%; moderate grade 90% and high grade 5.71% of samples. Statistical analysis revealed that Bax gene (p=0.000) expression was significantly increased in samples stage I and underexpressed in samples stage IIIA. The Bcl-2 gene was under-expressed in the majority of samples of the stage II. Even when the Bik gene was detected the protein level was over-expressed in 44.29% of the cases with noa significant correlation with apoptosis (TUNEL) (p=0.006). The samples where there were more alterations of the studied proteins were understood in the stages IIA (T2N0M0) and IIB (T2N1M0).
 
 Conclusions:
 The analysis of specimens of several patients in different stages of the disease turns out to be useful to establish a better diagnosis and prognosis. Differential regulation of these genes, especially Bik and Bax, may contribute to the biological nature of a clinically more aggressive and highly proliferative breast cancers.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4043.
Collapse
Affiliation(s)
- N Garcia-Hernandez
- 1 Laboratorio de Genetica Humana UIMGH, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - D Arenas
- 1 Laboratorio de Genetica Humana UIMGH, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - B Murillo-Ortiz
- 2 Unidad de Investigación Clinica UMAE No. 1 Bajio, Instituto Mexicano del Seguro Social, Leon, Guanajuato, Mexico
| | - A Meneses
- 3 Departamento de Patologia, Instituto Nacional de Cancerologia, Mexico, DF, Mexico
| | - D Muñoz
- 4 Departamento de Ginecologia, Instituto Nacional de Cancerologia, Mexico, DF, Mexico
| | - E Ruiz-Garcia
- 5 Laboratorio de Oncologia Molecular UIMEO, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| | - H Astudillo-de la Vega
- 5 Laboratorio de Oncologia Molecular UIMEO, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
| |
Collapse
|
21
|
Maldonado H, Perea-Montoya C, Cano S, De la Cruz J, Benitez-Galeana A, Ruiz-Garcia E, Silva J, Torres- Lopez J, Astudillo-de la Vega H. PCNA as potential marker for cervix neoplastic and preneoplastic lesions. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.16581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
García-Hernández N, Arenas D, Salamanca F, Calderon-Garcidueñas A, Ruiz-Garcia E, Silva J, Astudillo-de la Vega H. Proteomic analysis for NBK, Bcl-2, Bax genes and apoptosis (TUNEL) in breast cancer biopsies (stage II/III) by tissue microarray technology. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Astudillo-De La Vega H, Ruiz-Garcia E, Salcedo M, Torres A, De La Cruz JA, Benitez A, Gariglio P, Gutierrez-Delgado F. Outcomes associated with retinoblastoma and c-myc gene expression in patients with testicular cancer: A ten-year experience. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14656 Purpose: To determine and correlate the protein and mRNA expression of c-myc and Rb genes in normal testicular tissue and testicular cancer as possible markers of pharmacological response. Methods: Eleven fresh testicular cancer surgical specimens were obtained from untreated patients with histological diagnosis of seminoma (9/11) and non seminoma (2/11) during the period of 1992 to 1995. Age patient average was 35 (16–74). Two normal human testicular tissues also were evaluated as control. Single and double immunohistochemical assay was performed with peroxidase anti-peroxidase system using polyclonal antibody anti-pRb C-15 and monoclonal antibody anti- c-myc 1. Non radioactive in situ hybridization with cRNA probes was performed with cDNA from Rb (exons 2–27) and c-myc (exons 2,3). All seminomas were stage I and were treated with radiotherapy. Non-seminomas were stage III and were treated with chemotherapy. Results: Histological findings: Rb protein was expressed in mature cells toward the lumen of normal testicular tissue while c-myc was located in basal cells but decreasing the expression toward the lumen. High correlation between mRNA and protein levels for both genes was observed in normal testicular tissue. Rb protein and mRNA was absent in 6/11 (55%) tumors while the remaining showed a low level expression (45%). A high c-myc expression was observed in 6/11 (55%) seminomas specimens correlating in a few cases with absent Rb expression. Percentage of positive cells to c-myc gene expression (mRNA and protein) was highly increased in tumoral samples. Clinical findings: All patients with seminoma (9/11) and one of non seminoma (1/11) are alive and without tumoral activity a ten years of the diagnosis. A non-seminoma patient (1/11) have 11-year survival, a high expression of c-myc gene and absent retinoblastoma expression was observed in this case. Conclusion: The semiquantitative differences observed on c-myc and Rb gene expression in seminoma and non-seminoma tumors might correlate with the biological behavior including their high proliferation rate and the chemosensitivity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Astudillo-De La Vega
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - E. Ruiz-Garcia
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - M. Salcedo
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - A. Torres
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - J. A. De La Cruz
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - A. Benitez
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - P. Gariglio
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| | - F. Gutierrez-Delgado
- IMSS, Mexico D. F., Mexico; Acapulco Oncology Group, Acapulco, Mexico; CINVESTAV-IPN, Mexico City, Mexico; CEPREC-UNAM, Istmo de Tehuantepec, Mexico
| |
Collapse
|